by Michael Monostra Fact Checked by Richard Smith from Endocrine Today/Healio News
Published April 25, 2025
According to findings from a microsimulation model, covering obesity medications under Medicare Part D is projected to significantly increase federal spending, estimated at $47.7 billion over ten years. While these drugs may reduce healthcare costs associated with obesity-related conditions, these savings are currently not projected to outweigh the high prices of the medications. The cost projections are sensitive to variables like drug uptake rates, adherence to therapy, and potential price discounts. The research suggests a need for lower drug prices and continued investigation into cost-effective long-term weight management strategies.
Audio Overview
(from Google NotebookLM) (11 minutes)
